Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Ideaya Biosciences stock
Learn how to easily invest in Ideaya Biosciences stock.
Ideaya Biosciences Inc is a biotechnology business based in the US. Ideaya Biosciences shares (IDYA) are listed on the NASDAQ and all prices are listed in US Dollars. Ideaya Biosciences employs 91 staff and has a trailing 12-month revenue of around $29.1 million.
How to buy shares in Ideaya Biosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IDYA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Ideaya Biosciences stock price (NASDAQ: IDYA)Use our graph to track the performance of IDYA stocks over time.
Ideaya Biosciences shares at a glance
|Latest market close||$14.11|
|52-week range||$8.14 - $27.26|
|50-day moving average||$12.56|
|200-day moving average||$13.75|
|Wall St. target price||$21.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-1.48|
Buy Ideaya Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Ideaya Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ideaya Biosciences price performance over time
|1 week (2022-09-23)||16.61%|
|1 month (2022-09-01)||43.98%|
|3 months (2022-07-01)||-1.47%|
|6 months (2022-04-01)||23.77%|
|1 year (2021-10-01)||-44.75%|
|2 years (2020-10-01)||8.54%|
|3 years (2019-10-01)||55.40%|
|5 years (2017-09-27)||N/A|
Ideaya Biosciences financials
|Revenue TTM||$29.1 million|
|Gross profit TTM||$-30,217,000|
|Return on assets TTM||-12.53%|
|Return on equity TTM||-25.85%|
|Market capitalisation||$581.6 million|
TTM: trailing 12 months
Ideaya Biosciences share dividends
We're not expecting Ideaya Biosciences to pay a dividend over the next 12 months.
Ideaya Biosciences share price volatility
Over the last 12 months, Ideaya Biosciences's shares have ranged in value from as little as $8.14 up to $27.255. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ideaya Biosciences's is 1.4981. This would suggest that Ideaya Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ideaya Biosciences overview
IDEAYA Biosciences, Inc. , a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc.
Ideaya Biosciences in the news
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has caught the attention of institutional investors who hold a sizeable 50% stake
IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Announces Pricing of Public Offering of Common Stock
Frequently asked questionsWhat percentage of Ideaya Biosciences is owned by insiders or institutions?
Currently 5.303% of Ideaya Biosciences shares are held by insiders and 74.278% by institutions. How many people work for Ideaya Biosciences?
Latest data suggests 91 work at Ideaya Biosciences. When does the fiscal year end for Ideaya Biosciences?
Ideaya Biosciences's fiscal year ends in December. Where is Ideaya Biosciences based?
Ideaya Biosciences's address is: 7000 Shoreline Court, South San Francisco, CA, United States, 94080 What is Ideaya Biosciences's ISIN number?
Ideaya Biosciences's international securities identification number is: US45166A1025
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert